前列腺癌胚系突变:个体化医学证据的系统综述
该系统综述检索2000至2022年英文文献,最终纳入50篇分析前列腺癌胚系突变的遗传基础与临床意义。结果显示同源重组基因和错配修复基因等胚系突变与前列腺癌发生及侵袭性相关,支持对家族史阳性、高危或转移性前列腺癌患者进行胚系基因检测。
要点
- 同源重组基因(BRCA1/2、ATM、CHECK2)和错配修复基因等胚系突变与前列腺癌发生及侵袭性相关。
- 局限性前列腺癌伴某些基因突变者更易发展为侵袭性癌,积极治疗可能优于主动监测。
- 转移性前列腺癌中这些基因改变可能作为PARP抑制剂疗效预测的生物标志物。
核心结论
- 胚系检测和遗传咨询在前列腺癌筛查及治疗决策中具有越来越重要的意义。
- 证据支持近期指南推荐对前列腺癌家族史阳性、高危或转移性疾病的男性考虑胚系基因检测。
研究设计与样本
- 系统检索PubMed、Web of Science和ClinicalTrials.gov,纳入2000至2022年英文文献,遵循PRISMA指南。
- 检索识别980篇文献,筛选前去除200篇(重复、非英文、2000年前发表),标题/摘要筛选后排除245篇,最终纳入50篇分析。
主要发现
- 同源重组基因(BRCA1/2、ATM、CHECK2)、错配修复基因(MLH1、MLH2、MSH6)及其他基因的胚系突变与前列腺癌的发生和侵袭性相关。
- 局限性前列腺癌伴某些基因突变者更可能发展为侵袭性癌,因此积极治疗可能优于主动监测。
- 转移性前列腺癌中这些基因改变可能是有用的生物标志物,用于预测对PARP抑制剂等特定治疗的反应。
关键数值与推荐
- 与其他男性癌症相比,前列腺癌遗传易感性比例很高,归因于遗传因素的癌症估计比例为5-15%。
- PARP抑制剂近期已获批用于治疗转移性去势抵抗性前列腺癌。
临床怎么用
- 作者认为,对前列腺癌家族史阳性、高危或转移性疾病的男性,应考虑胚系基因检测。
- 作者认为,伴某些基因突变的局限性前列腺癌患者,积极治疗可能优于主动监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of precision medicine in prostate cancer (PCa) is to individualize the treatment according to the patient's germline mutation status. PCa has a very high rate of genetic predisposition compared with other cancers in men, with an estimated rate of cancers ascribable to hereditary factors of 5-15%. METHODS: A systematic search (PubMed, Web of Science, and ClinicalTrials.gov) of English literature from 2000 to 2022, using the keywords "prostate cancer", "germline mutations", "family history", and "inheritance" was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. RESULTS: The search identified 980 publications. Of these, 200 papers were removed before screening (duplicates, non-English literature, and publication year before 2000) and 245 records were excluded after title/abstract screening. Finally, 50 articles were included in the final analysis. We analyze the latest evidence on the genetic basis of PCa predisposition and clinical implications for more personalized screening protocols and therapeutic management of this high-prevalent cancer. DISCUSSION: Emerging data show that germline mutations in homologous recombination genes (BRCA1/2, ATM, CHECK2), in mismatch repair genes (MLH1, MLH2, MSH6), and other additional genes are associated with the development and aggressiveness of PCa. Germline testing and genetic counseling have increasingly important implications in cancer screening and therapeutic decisions making for patients affected by PCa. Patients with localized PCa and some gene mutations are more likely to develop aggressive cancer, so active treatment may be preferable to active surveillance for these patients. Moreover, in patients with metastatic PCa, these gene alterations may be useful biomarkers for predicting response to specific therapy such as PARP inhibitors, recently approved for the treatment of metastatic castration-resistant PCa. The evidence supports recent guidelines and recommendations considering germline genetic testing for patients with a positive family history of PCa or men with high risk or metastatic disease.
引用
- Marino F, Totaro A, Gandi C, et al. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. Prostate Cancer Prostatic Dis. 2022. PMID: 36434163. doi:10.1038/s41391-022-00609-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。